Clinical trials: Complication of Treatment
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer
RATIONALE: Estrogen can stimulate the growth of ovarian cancer cells. Hormone therapy using arzoxifene hydrochloride may fight ovarian or peritoneal cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00003670
- Testing
- arzoxifene hydrochloride
- Where
- 4 sites in United States
- Sponsor
- Eli Lilly and Company
IgA Nephropathy (IgAN)
Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN
- Trial name
- NCT07390123
- Testing
- HSK39297
- Where
- 9 sites in China
- Volunteers
- 370 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Bacterial Vaginosis
Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis
The purpose of this study was to demonstrate comparable efficacy, safety, and tolerability of Teva Pharmaceuticals USA's generic formulation of Metronidazole Vaginal Gel, 0.75% and 3M Pharmaceuticals' MetroGel-Vaginal®…
- Trial name
- NCT01020396
- Testing
- Metronidazole
- Where
- 37 sites in United States
- Volunteers
- 579 people
- Sponsor
- Teva Pharmaceuticals USA
Ovarian Cancer
A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation
Study population will consist of HRD+ (BRCAm +/- positive genomic instability score according to used test system) OC with available medical history.
- Trial name
- OVARD (NCT05918042)
- Where
- 24 sites in Russia
- Volunteers
- 414 people
- Sponsor
- AstraZeneca
Urinary Stone
Study of an Enhanced Lithotripsy System (ELS) in the Treatment of Urinary Stone Disease
This is a single arm, multi-center study to assess the safety and efficacy of a form of extracorporeally induced lithotripsy, called the Enhanced Lithotripsy System, to treat urinary stones.
- Trial name
- STONES (NCT04771182)
- Testing
- Enhanced Lithotripsy System
- Where
- 4 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Avvio Medical
Endometriosis
Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life
The study aims to collect data on the influence of a treatment with Visanne (Dienogest 2mg/d) on the Endometriosis related quality of life.
- Trial name
- DIVA (NCT01595724)
- Testing
- Visanne (Dienogest, BAY86-5258)
- Where
- 11 sites in Belarus, Egypt and 9 more
- Volunteers
- 3,006 people
- Sponsor
- Bayer
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Endometriosis, Endometriosis Ovary
Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis
Background: Endometriosis is a chronic gynecological disease with the growth of endometrial tissue outside the endometrium. In all its properties, this tissue is similar to the mucous membrane of the uterus.
- Conditions
- Endometriosis, Endometriosis Ovary, Endometriosis Externa, Endometriosis, Rectum
- Trial name
- ELTA (NCT03481842)
- Testing
- Linifanib, BIBW2992, Axitinib
- Where
- Switzerland
- Sponsor
- BioGene Pharmaceutical Ltd.
Renal Failure, End Stage Renal Disease
Safety and Clinical Performance of a Dialyzer With a Modified Polysulfone Membrane
The clinical investigation will be performed to generate clinical data on clearances and removal rates (for ß2-microglobulin, myoglobin, phosphate, creatinine, and urea) as well as biocompatibility of the modified polysulfone…
- Trial name
- eMPORA (NCT03315624)
- Testing
- Dialyzer
- Where
- Germany
- Volunteers
- 49 people
- Sponsor
- Fresenius Medical Care Deutschland GmbH
Atrophy, Vaginal Atrophy
Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects
The purpose of this study is to assess the use of the Alma CO2 Pixel FemiLift™ in the treatment of VulvoVaginal Atrophy (VVA) in postmenopausal female subjects.
- Conditions
- Atrophy, Vaginal Atrophy, Genital Diseases, Female
- Trial name
- NCT02747641
- Testing
- Pixel CO2 Laser System
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Alma Lasers Inc.
Heart Failure, Cardio-Renal Syndrome
A Clinical Study of the Safety and Efficacy of a Wearable Device (CLS UF) That Delivers Continuous Administration of Glucose to Recirculated Peritoneal Dialysis Fluid for the Purpose of Ultrafiltration in Patients With Congestive Heart Failure
A single-center, prospective, non-randomized, clinical and first-in-human study. Each patient will be studied during a single treatment session of ten hours.
- Trial name
- NCT02772146
- Testing
- CLS UF
- Where
- Germany
- Volunteers
- 2 people
- Sponsor
- Triomed AB
Gynecologic Cancer, Colorectal Cancer
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
Long-Term Follow-Up Study for Subjects Enrolled in the Phase I/II Study of Autologous T Cells Engineered using the Sleeping Beauty System to Express T cell Receptors (TCRs) Reactive Against Cancer-specific Mutations in Subjects…
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05292859
- Testing
- Neoantigen specific TCR-T cell drug product
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis
Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)
The purpose of this study is evaluate if abatacept is effective and safe in decreasing the level of protein loss in the urine in patients with excessive loss of protein in the urine (nephrotic syndrome) due to either focal…
- Conditions
- Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT02592798
- Testing
- Abatacept, Normal Saline, D5W
- Where
- 27 sites in United States
- Volunteers
- 36 people
- Sponsor
- Bristol-Myers Squibb
Overactive Bladder
A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)
This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy, safety, and tolerability of solabegron modified release low dose or high dose tablets…
- Trial name
- VEL-2001 (NCT03594058)
- Testing
- Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose
- Where
- 77 sites in United States
- Volunteers
- 1,413 people
- Sponsor
- Velicept Therapeutics, Inc.
Diabetic Foot Ulcer
Safety and Efficacy of HO/03/03 10μg in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers
A prospective, double blind, randomized, placebo controlled, outpatient, parallel group comparison trial to assess the safety and efficacy of HO/03/03 10µg versus Placebo, applied topically once daily for up to 14 weeks in at…
- Trial name
- Truheal (NCT00926068)
- Testing
- HO/03/03 10µg
- Where
- 33 sites in United States, India
- Volunteers
- 196 people
- Sponsor
- HealOr
Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE)
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Lupus Nephritis Refractory to Standard Therapy
This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of autologous anti-CD20/BCMA chimeric antigen receptor T cells (C-CAR168) following lymphodepleting chemotherapy in…
- Conditions
- Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases
- Trial name
- NCT07729826
- Testing
- C-CAR168
- Volunteers
- 50 people
- Sponsor
- AbelZeta Inc.
Parkinson's Disease
An Extension of Istradefylline in Parkinson's Disease Patients Who Have Completed Studies 6002-EU-007, 6002-US-013 or 6002-US-018
This is a 1-year, open-label, long-term safety extension for patients who have completed prior istradefylline studies 6002-EU-007, 6002-US-013 or 6002-US-018.
- Trial name
- NCT00199368
- Testing
- Istradefylline ( KW-6002)
- Where
- United States
- Volunteers
- 1,100 people
- Sponsor
- Kyowa Kirin, Inc.
Urinary Bladder, Overactive
A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients
To evaluate the efficacy and safety of solifenacin succinate (Vesicare) 5mg OD in subjects with overactive bladder compared to tolterodine wmg, bid
- Trial name
- NCT00368706
- Testing
- solifenacin succinate, tolterodine
- Where
- 4 sites in China
- Volunteers
- 246 people
- Sponsor
- Astellas Pharma Inc
Advanced Parkinson's Disease
An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications
This is an extension study to evaluate the long-term safety and tolerability of ABT-SLV187 in subjects with advanced Parkinson's disease.
- Trial name
- NCT02082249
- Testing
- ABT-SLV187
- Where
- 7 sites in Japan, South Korea and 1 more
- Volunteers
- 30 people
- Sponsor
- AbbVie
Urinary Incontinence
A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity
This study will evaluate the long-term safety and efficacy of onabotulinumtoxinA (botulinum toxin Type A; BOTOX®) for the treatment of urinary incontinence due to neurogenic detrusor overactivity in participants who successfully…
- Trial name
- NCT01852058
- Testing
- OnabotulinumtoxinA
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 95 people
- Sponsor
- Allergan
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.